Home > Selected Past Studies

SELECTED PAST STUDIES - All Cancers - Lung Cancer

Study

Disease

type & number of samples

Specific Requirements

associated data required

LC-1

Non-Small Cell Lung Carcinoma

FFPE Blocks

Retrospective

More than 3500 subjects

  • 6 FFPE sections for screening of a specific mutation
  • The corresponding FFPE blocks should remain available until the selection of positive blocks is completed
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)

LC-2

Non-Small Cell Lung Carcinoma & Squamous Cell Lung Carcinoma

Tissue Microarrays (TMA)

Prospective

More than 1000 subjects

4 groups:

  • 50% Squamous cell Lung Carcinoma
  • 4 groups (one group per stage)
  • 50% Primary Lung Adenocarcinoma
  • 4 groups (one group per stage)
  • SCLC and NSCLC primo diagnosis
  • No Asian subjects
  • Also 5 FFPE slices placed in Eppendorf tube and one stained slide defining the punched area
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade), % tumor cells in sample
  • Smoking status
  • Clinical history including Disease-free survival, Overall survival
  • IHC results

LC-3

Non-Small Cell Lung Cancer (ALK)

FFPE Blocks

Retrospective

More than 150 subjects

  • NSCLC with positive Anaplastic Lymphoma Kinase (ALK+) rearrangements
  • Several biobanks can participate with a minimum of 10 cases/biobank
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)
  • Method used for determination of ALK positivity

LC-4

Non-Small Cell Lung Cancer (PD-L1)

Plasma

Prospective

More than 30 subjects

  • Positive for FFPE PD-L1 expression assessed by ICH
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)

LC-5

Non-Small Cell Lung Cancer (PD-L1)

FFPE Blocks

Retrospective

More than 30 subjects

  • PD-L1 expression assessed by ICH
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)

LC-6

Non-Small Cell Lung Cancer (ALK)

Whole Blood and Matched FFPE Blocks

Prospective

More than 40 subjects

  • 20ml of whole blood
  • The tissue and blood collection must have been done with a maximum of 1 month from each other
  • Whole blood collected in 2 different types of tubes and shipped at room temperature
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)
  • Treatment History

LC-7

Non-Small Cell Lung Cancer (EGFR)

FFPE Blocks

Prospective

More than 40 subjects

  • Locally advanced or metastatic NSCLC – stage IIIB or IV treated by EGFR tyrosine kinase inhibitors
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)
  • EGFR mutation status
  • Treatment History and medical out-come
  • Treatment response to EGFR tyrosine kinase inhibitors treatment

LC-8

Non-Small Cell Lung Cancer (EGFR)

FFPE Blocks

Retrospective

More than 50 subjects

  • Primary tumor or metastasis
  • Progression on prior first-line therapy with different EGFR tyrosine kinase inhibitors
  • Tissue must have been obtained after progression.
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)
  • Treatment History
  • Mutation data (point mutation in Exons)

LC-9

Non-Small Cell Lung Cancer (EGFR)

Plasma

Prospective

More than 300 subjects

2 groups:

  • Stage III and IV NSCLC with mutated EGFR
  • Stage III and IV NSCLC non-smokers women and/or Asians
  • EDTA plasma aliquoted in 5 Eppendorf tubes
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)
  • Treatment History and medical out-come
  • Alcohol and smoking history

LC-10

Non-Small Cell Lung Carcinoma

FFPE Block and PBMC

Retrospective

More than 50 subjects

  • FFPE block and PBMC collected at diagnosis, before start of any treatment
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)
  • Treatment History and medical out-come
  • If available, biomarker status: cMET, PI3K, EGFR, PTEN, ALK, ROS1, BRAF, HER2, NRAS…

LC-11

Non-Small Cell Lung Carcinoma

FFPE Blocks

Retrospective

More than 100 subjects

  • FFPE surgery resected tissue blocks
  • Any stage
  • Patients newly diagnosed and prior to treatment
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)
  • Treatment History
  • 5 years medical follow-up

LC-12

Non-Small Cell Lung Carcinoma

Whole Blood

Retrospective

More than 100 subjects

  • Stage IV NSCLC subjects
  • Only chemotherapy naïve donors
  • Blood sample collected directly into specific tubes and transported at room Temperature (16-25OC)
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)
  • Treatment History and medical out-come

LC-13

Non-Small Cell Lung Cancer

Serum

Retrospective

More than 300 subjects

10 groups

  • Stage I NSCLC adenocarcinoma, smokers and survived < 5 years from diagnosis
  • Stage I NSCLC adenocarcinoma, smokers and survived > 5 years from diagnosis
  • Stage I NSCLC adenocarcinoma, never-smokers and survived < 5 years from diagnosis
  • Stage I NSCLC adenocarcinoma, never-smokers who survived > 5 years from diagnosis
  • Stage II NSCLC adenocarcinoma, smokers and survived < 5 years from diagnosis
  • Stage II NSCLC adenocarcinoma, smokers and survived > 5 years from diagnosis
  • Mesothelioma
  • IPF, bronchiectasis, asthma or pulmonary tuberculosis
  • SCLC
  • Healthy control subjects.
  • Collection within 1 month of confirmed diagnosis and prior to start of any drug treatment or surgery
  • Must not have had drug treatment associated to pulmonary disease in the 3 months prior to sample collection 
  • Must not have had surgery associate with pulmonary disease
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)
  • Treatment History and medical out-come
  • Smoking habits

LC-14

Non-Small Cell Lung Cancer (KRAS)

FFPE Blocks

Retrospective

More than 35 subjects

  • Known KRAS codon 12 and 13 mutation status
  • Any NSCLC subtype, any stage
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)
  • Method used to detect KRAS mutation

LC-15

Small Cell Lung Carcinoma

FFPE Blocks

Retrospective

More than 180 subjects

  • Any stage
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)

LC-16

Mesothelioma

FFPE Blocks

Retrospective

More than 180 subjects

  • Samples collected over the past 4 years
  • Age, gender
  • Date of sample collection
  • Stage

OC-1

Uveal Melanoma

FFPE Blocks

Retrospective

More than 15 subjects

  • Diagnosed with Uveal Melanoma
  • Age, Gender, Ethnicity
  • Sample collection date
  • Tumor location and size
  • Pathological diagnosis

OC-2

Parotid Gland Cancer

FFPE Blocks

Retrospective

More than 15 subjects

  • Advanced and metastatic
  • Age, Gender, Ethnicity
  • Medical history
  • Tumor location and size
  • Pathological diagnosis

OC-3

Thyroid Cancer

FFPE and Matched Frozen Tissue

Retrospective

More than 10 subjects

  • 50% Medullary carcinoma and 50% parafollicular hyperplasia
  • Diagnosed with thyroid cancer
  • Age, Gender, Ethnicity
  • Sample collection date
  • Pathological diagnosis
  • Medical history

OC-4

Fallopian Tube Cancer

FFPE Blocks

Retrospective

More than 40 subjects

  • Stage IIIB or higher
  • Age, Gender, Ethnicity
  • TNM
  • Medical history 
  • Pathology diagnosis

OC-5

Pheochromocytoma

Plasma and Matched Frozen Tissue or FFPE

Retrospective

More than 50 subjects

2 groups:

  • 50% subjects with benign pheochromocytoma
  • 50% subjects with malignant pheochromocytoma
  • Pre-surgery plasma samples only
  • Ischemia time < 1 hour for tissue
  • Age, Gender, Ethnicity
  • Sample collection date
  • Clinical data
  • Treatment history

OC-6

Head & Neck Cancer

FFPE

Retrospective

More than 40 subjects

6 groups:

  • Tongue
  • Larynx
  • Nasopharynx
  • Oropharynx
  • Tonsil
  • Hypopharynx
  • Squamous Cell Carcinoma
  • Age, Gender, Ethnicity
  • TNM
  • Clinical data
  • Pathology diagnosis